Ming-Zhi H
Department of Interventional Radiology, Fujian Provincial Tumor Hospital, Fuzhou 350014, Fujian, P. R. China

Qiang C
Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fuzhou 350014, Fujian Province, P. R. China

Hai-Lan L
Department of Interventional Radiology, Fujian Provincial Tumor Hospital,, Fuzhou 350014, Fujian, P. R. China

Hui W
Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fuzhou 350014, Fujian Province, P. R. China

Qi-Zhong C
Department of Interventional Radiology, Fujian Provincial Tumor Hospital, Fuzhou 350014, Fujian Province, P. R. China

Jian-Cheng L
Department of Radiation Oncology, Fujian Provincial Tumor Hospital, Fuzhou 350014, Fujian Province, P. R. China

Jian-Xiong Z
Department of Interventional Radiology, Fujian Provincial Tumor Hospital, Fuzhou 350014, Fujian Province, P. R. China

Yun-Bin Y
Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fuzhou 350014, Fujian Province, P. R. China

Correspondence:

Chen Qiang, M.D.
Department: Department of Medical Oncology, Fujian Provincial Tumor Hospital
Address: No. 91, Fengban maluding, Fuma Road
City: Fuzhou 350014, Fujian Province
Country: P. R. China
E-mail: cqiang8@pub5.fz.fj.cn
Tel: +86 0591 8366 0063
Fax: +86 0591 8366 0063

1.  Parkin DM, Bray F,  Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6. [PubMed]

2.  Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200-7. [PubMed]

3.  Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol. 1983;19(8):1053-65. [PubMed]

4.  Ohishi H, Uchida H, Yoshimura H, et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology. 1985;154(1):25-9. [PubMed]

5.  Yumoto Y, Jinno K, Tokuyama K, et al. Hepatocellular carcinoma detected by iodized oil. Radiology. 1985;154(1):19-24. [PubMed]

6.  Llovet JM, Real MI, Mont ana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359(9319):1734-9. [PubMed]

7.  Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-71. [PubMed]

8.  Taieb J, Mansourbakht T, Ducreux M, et al., editors. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma (AHCC): results of a phase II study. Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition); 2004.

9.  Bearz A, Sorio R, Tommasi G, et al. Oxaliplatin and 5-fluorouracil in hepatocarcinoma. Proc Am Soc Clin Onco. 2001;20:148b.

10.  Yang TS, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2000;89(4):750-6. [PubMed]

11.  Horiuchi H, Ishikawa H, Hiraki M, et al. [Intra-arterial chemotherapy with gemcitabine (GEM) for unresectable pancreatic cancer]. Gan To Kagaku Ryoho. 2002;29(12):2065-9. [PubMed]

12.  Vogl TJ, Heller M, Zangos S, et al. [Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence]. Rofo. 2003;175(5):695-704. [PubMed]

13.  Shamseddine AI, Khalifeh MJ, Mourad FH, et al. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. Clin Pharmacokinet. 2005;44(9):957-67. [PubMed]

14.  Yang BH. [The Diagnosing and Staging National Standards for hepatocellular carcinoma]. Zhonghua Ganzangbing Zazhi. 2001;9(6):324-9.

15.  Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16. [PubMed]

16.  Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429-42. [PubMed]

17.  Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969-77. [PubMed]

18.  Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Macdonald JS. Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs. 1997;15(3):257-60. [PubMed]

19.  O'Reilly EM, Stuart KE, Sanz-Altamira PM, et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer. 2001;91(1):101-5. [PubMed]

20.  Rougier P, Ducreux M, Kerr D, et al. A phase II study of raltitrexed (‘Tomudex') in patients with hepatocellular carcinoma. Ann Oncol. 1997;8(5):500-2. [PubMed]

21.  Chao Y, Chan WK, Birkhofer MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998;78(1):34-9. [PubMed]

22.  Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer. 2000;88(7):1574-81. [PubMed]

23.  Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918-28. [PubMed]

24.  Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989;64(8):1700-7. [PubMed]

25.  Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34. [PubMed]